TY  - GEN
AU  - Casali,Paolo G
AU  - Le Cesne,Axel
AU  - Poveda Velasco,Andres
AU  - Kotasek,Dusan
AU  - Rutkowski,Piotr
AU  - Hohenberger,Peter
AU  - Fumagalli,Elena
AU  - Judson,Ian R
AU  - Italiano,Antoine
AU  - Gelderblom,Hans
AU  - Adenis,Antoine
AU  - Hartmann,Jörg T
AU  - Duffaud,Florence
AU  - Goldstein,David
AU  - Broto,Javier M
AU  - Gronchi,Alessandro
AU  - Dei Tos,Angelo P
AU  - Marréaud,Sandrine
AU  - van der Graaf,Winette T A
AU  - Zalcberg,John R
AU  - Litière,Saskia
AU  - Blay,Jean-Yves
TI  - Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
SN  - 1527-7755
PY  - 2016///0428
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Australasia
KW  - Chemotherapy, Adjuvant
KW  - Disease-Free Survival
KW  - European Union
KW  - Female
KW  - Follow-Up Studies
KW  - Gastrointestinal Neoplasms
KW  - drug therapy
KW  - Gastrointestinal Stromal Tumors
KW  - Humans
KW  - Imatinib Mesylate
KW  - therapeutic use
KW  - International Cooperation
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - methods
KW  - Neoplasm Recurrence, Local
KW  - Odds Ratio
KW  - Protein Kinase Inhibitors
KW  - Protein-Tyrosine Kinases
KW  - antagonists & inhibitors
KW  - Salvage Therapy
KW  - Treatment Failure
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2015.62.4304
ER  -